Heart health

Smartphone-based interventions showed promise for increasing physical activity, but results for clinical risk-factor measurements were mixed. Several changes were not statistically significant. The review therefore does not support treating all digital programs as equally effective, or assuming that increased activity necessarily translates into improved blood pressure, glucose, blood lipids or body weight.

Keep in mind: The abstract provides no effect sizes, detailed comparison conditions or follow-up lengths. Limited representation from lower-income settings also leaves uncertainty about whether the findings transfer to different healthcare systems and user populations.

People who had both type 2 diabetes and cardiovascular disease had higher odds of falls than those with diabetes alone. The review supports an association, but cannot show that cardiovascular disease caused the falls. It also leaves uncertainty about which cardiovascular conditions or underlying processes account for the observed pattern.

Keep in mind: Study methods, outcome measures and participant groups differed, limiting firm conclusions. This abstract-based account lacks follow-up lengths and absolute fall probabilities, so it cannot establish how large the difference was in everyday terms.

The pooled pairwise comparison favored tenecteplase for excellent functional outcomes. It detected no significant differences in good or poor functional outcomes, major neurological improvement within 72 hours, symptomatic bleeding inside the skull, or mortality at 90 days. Separate network comparisons found advantages for particular doses on specific functional outcomes.

Keep in mind: The abstract omits functional-outcome assessment timing and absolute outcome rates. Nonsignificant safety findings do not establish equivalence, and treatment rankings alone cannot establish a safety advantage.

The pooled trials suggest that intravenous iron can improve some outcomes for people who have both heart failure and iron deficiency. Hospitalization outcomes and cardiovascular deaths favored iron treatment, but deaths from any cause did not show a statistically significant reduction. These findings do not establish an overall survival benefit.

Keep in mind: The abstract omits follow-up lengths, control-treatment details, and absolute event rates. This abstract-based account therefore cannot establish the absolute benefit or how long it lasts.

The human trial analyses reported lower blood pressure with prebiotics among participants with hypertension. Estimates pooling participants with and without hypertension were compatible with no difference. This pattern does not establish that hypertension status changes the response to prebiotics, and reported gut changes do not establish the mechanism behind the blood pressure findings.

Keep in mind: This abstract-based explanation cannot resolve missing comparator details or intervention lengths. The abstract reports no interaction test establishing different responses by hypertension status, and findings from animal studies cannot be treated as direct evidence for patients.

The indirect comparison favored P2Y12 inhibitor monotherapy for a combined endpoint of ischemic and bleeding events after shortened dual therapy. Any bleeding was also lower, although accounting for differences in preceding treatment duration weakened that finding. The combined endpoint remained favorable, but the abstract does not provide absolute event rates.

Keep in mind: This abstract-based explanation relies on an indirect comparison between monotherapies. Trials differed in preceding dual-therapy duration and used their own composite endpoint definitions. A common follow-up length and absolute event rates are not reported.

Adding EPA to statins produced greater reductions in total and lipid plaque volumes than statins alone. The mixed EPA/DHA comparison was not statistically significant. These results concern coronary imaging measurements, rather than heart attacks or survival, and differing significance across comparisons does not by itself establish that EPA outperforms the mixture.

Keep in mind: The abstract does not report treatment duration, doses, or a direct EPA-versus-mixture effect estimate. Its plaque measurements cannot establish the size or existence of a benefit for clinical cardiovascular events.

Among the older adults studied, intensive blood pressure control reduced pooled cardiovascular events and deaths from any cause. Stroke incidence did not differ significantly, and serious adverse events showed no statistically detectable difference. These results concern the trial populations and do not establish the most appropriate target for every older person.

Keep in mind: This abstract-based account lacks follow-up duration, absolute event rates and detailed participant characteristics. Those omissions limit assessment of the absolute benefit and applicability to an individual patient.

The authors report associations between genetic variation, how the body handles oral anticoagulants, and bleeding or stroke outcomes, especially for dabigatran and apixaban. However, the abstract does not establish that choosing treatment through genetic testing improves patient outcomes. Its reported risk thresholds lack enough context to give readers a dependable estimate of personal risk.

Keep in mind: This abstract-based explanation cannot assess the underlying studies or model validation. The abstract does not specify reference groups, follow-up periods or how its risk thresholds were derived, limiting interpretation of the reported clinical risks.

Adding nicotinamide riboside to supervised walking did not reduce daytime systolic blood pressure more than adding placebo. Supplement groups had higher levels of NAD breakdown products, but that biological response did not establish improved blood pressure control. Exploratory nighttime findings in participants without antihypertensive medication remain uncertain and require further testing.

Keep in mind: This abstract-based summary concerns a short pilot trial. The nighttime blood pressure signal came from a post hoc subgroup analysis and was described as a trend, limiting its value as evidence of benefit.

For Black women with cardiovascular disease or high risk, meditation did not show a significant advantage over health education in artery-wall thickness or blood pressure after a year. Some blood-sugar and cholesterol measures favored meditation. These mixed results concern risk markers and do not establish that meditation prevented heart attacks, strokes or other cardiovascular events.

Keep in mind: The comparison with historical controls was exploratory and conducted after the main analysis. The abstract does not supply effect sizes for most outcomes, and its weight-loss result applies only to participants with overweight or obesity.

In a small laboratory study, women with endometriosis showed smaller blood-pressure rises than healthy controls during cold exposure and handgrip testing, contrary to the researchers’ prediction. The aspirin-versus-placebo comparison detected no effect on these responses. These results describe brief physiological reactions and do not establish higher or lower cardiovascular risk, or aspirin’s effects on long-term health.

Keep in mind: The groups were small, and outcomes were laboratory pressure responses rather than cardiovascular events. Endometriosis status was not randomized, so the group differences cannot establish that endometriosis caused the altered responses.

Aerobic exercise improved blood pressure and several blood-fat measurements in postmenopausal women compared with control groups. Anxiety scores also improved, but depression and total cholesterol did not show statistically significant effects. These results describe measured risk factors and symptoms; they do not establish fewer cardiovascular events or durable mental-health benefits.

Keep in mind: The abstract does not report intervention durations or evidence-certainty ratings, although certainty was assessed. The authors call for longer-term clinical outcomes, leaving effects on cardiovascular events and lasting health changes unresolved.

The review reported lower blood pressure estimates for several dietary patterns, with its largest reported differences in a category called food-based oil diets. However, the abstract does not define that category or name the comparison diets. Because trials and observational studies were included, these summaries do not by themselves establish a causal ranking of diets.

Keep in mind: Reference diets, intervention durations, and result confidence intervals are missing. The abstract does not separate randomized findings from observational associations, making the reported differences difficult to interpret.

In transgender adults, starting feminizing hormone therapy was associated with a longer QTc, an interval measured on a heart electrical tracing; starting testosterone was associated with a shorter interval. These findings concern an electrical measurement. They do not show that either treatment caused more or fewer abnormal heart rhythms or other cardiovascular events.

Keep in mind: This was an observational study from one center, with a smaller subgroup measured before and after treatment initiation. The abstract does not report cardiovascular event outcomes or individual follow-up lengths.

This review asked whether sacubitril/valsartan use in people with heart failure was associated with greater dementia risk. Instead, the pooled findings linked its use to lower risk of dementia from any cause than comparison treatments. Because the abstract does not describe the underlying study designs, this association cannot establish that the medicine prevents dementia.

Keep in mind: The abstract omits follow-up lengths, individual study designs and absolute dementia rates. This abstract-based summary cannot determine the absolute risk difference or explain how the association arose.

The pooled analysis found lower systolic and diastolic blood pressure with edible algae interventions, but results varied substantially across trials. These are blood-pressure measurements, rather than evidence of fewer cardiovascular events. Product and participant subgroups showed different results, while a separate analysis did not establish an independent association between algae dose and systolic pressure change.

Keep in mind: The abstract omits specific control treatments and details of individual trials. Variation between results limits how confidently the pooled effect applies to a particular algae product, participant group or intervention schedule.

Among inactive middle-aged adults, hotter water immersion after exercise produced a greater reduction in mean arterial pressure, an averaged blood pressure measure, than thermoneutral immersion after exercise. An artery-widening measurement also improved. The trial did not find additional improvements in fitness or several metabolic markers, and it does not establish lasting cardiovascular benefits.

Keep in mind: The trial was small and brief. The abstract gives no confidence interval for the blood pressure difference and does not establish longer-term effects or whether the findings apply to physically active adults.

The strongest evidence highlighted a medicine class called glucagon-like peptide-1 receptor agonists in people with type 2 diabetes or overweight/obesity. These medicines were associated with fewer deaths and several cardiovascular outcomes. Other approaches had differing results, while comprehensive lifestyle interventions showed no significant cardiovascular benefit. The review does not establish a single best approach across populations.

Keep in mind: Most evidence had moderate or low certainty because of bias, imprecise estimates, or inconsistent findings. The abstract does not provide effect sizes, follow-up lengths, or detailed comparison groups, preventing assessment of benefit magnitude.

For people undergoing atrial fibrillation ablation, the experimental compound 2-HOBA increased the odds of rhythm recurrence during early monitoring compared with placebo. The measured blood marker did not differ between groups. After treatment ended, no recurrence difference was detected during extended follow-up; this result does not establish equivalence or apply to every atrial fibrillation setting.

Keep in mind: This pilot concerned the period around ablation, and the abstract does not give the sample size or absolute recurrence rates. The authors explicitly leave generalizability to other atrial fibrillation settings unresolved.

For men in these trials, testosterone replacement increased reported heart rhythm disorders compared with placebo. The analysis did not detect statistically significant differences in overall deaths, cardiovascular deaths, strokes or heart attacks. Those uncertain results do not establish equal safety, and the rhythm finding should remain part of the overall interpretation.

Keep in mind: The abstract does not provide absolute event rates or describe which rhythm disorders occurred. It therefore cannot show how many additional men experienced an arrhythmia or how serious those events were.

During treatment for testosterone deficiency, triglycerides, HDL cholesterol and a blood sugar marker declined, while LDL cholesterol showed no statistically significant change. These were changes in laboratory measurements, rather than demonstrated improvements in heart health. Without randomized treatment allocation or a reported untreated comparison, the changes cannot be attributed to treatment alone.

Keep in mind: The cohort came from a single healthcare provider. The abstract cannot separate contributions from testosterone-deficiency treatment, lifestyle changes or other influences, and it does not report cardiovascular events.

In people already living with cardiovascular disease, higher concentrations of small HDL particles and total HDL particles were associated with lower mortality from any cause. Higher large-particle concentrations showed the opposite association. Small particles were also linked to lower cardiovascular mortality. These observational findings do not establish that changing particle levels would change someone’s survival.

Keep in mind: Follow-up lengths and adjustments for other factors are not described. The abstract reports relative risks but also refers to hazards, leaving the statistical measure unclear.

Sotatercept improved walking-test performance compared with placebo in adults with pulmonary arterial hypertension. The review also reported fewer deaths and cases of right ventricular failure, meaning failure of the heart's right pumping chamber. These findings came alongside an increased risk of low platelet counts; the abstract does not report follow-up duration.

Keep in mind: The abstract omits follow-up durations and absolute event counts for deaths and adverse effects. Those omissions limit assessment of how often benefits and harms occurred and whether differences persisted over time.